New combo therapy aims to keep leukemia away after transplant
NCT ID NCT07493408
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial tests whether adding asciminib to standard tyrosine kinase inhibitors can prevent relapse in patients with Philadelphia chromosome-positive B-cell acute lymphoblastic leukemia or blastic phase chronic myeloid leukemia after a stem cell transplant. 45 participants will be randomly assigned to receive asciminib plus standard drugs or standard drugs alone. The study will monitor relapse rates and side effects over time.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Asciminib
- What this could lead to
- If it works, this could reduce the chance of leukemia returning after a stem cell transplant, offering a new maintenance option.
- What could go wrong
- This is a small, early-phase trial (45 participants) that hasn't started yet. The added drug may cause side effects or not improve outcomes.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 2
Tests whether the treatment actually works, and watches for side effects, in a larger group.
- Participants
-
About 45 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
Mar 2026
An estimate. Start dates often move.
- Expected to finish
-
Dec 2037
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: 1. The subject (or the subject's legally acceptable representative, if applicable) must be capable of giving written informed consent and, prior to the commencement of any study-specific procedure, must sign an informed consent form (ICF) indicating the consent on the subject's voluntary participation in the study and compliance with the requirements and restrictions listed on the ICF. 2. Age ≥ 18 years 3. Patients with Ph+ B-ALL or CML-BP, who had undergone allogeneic HSCT 4. Patients must have received TKI therapy in induction/consolidation therapy 5. Absolute neutrophil count ≥ 1.0 × 109/L 6. Platelet count ≥ 50 × 109/L Exclusion Criteria: 1. Patients with known atypical transcript that cannot be measured by available polymerase chain reaction (PCR) methods. 2. Eastern Cooperative Oncology Group (ECOG) performance status ≥ 2 3. Uncontrolled hypertension 4. Corrected QT interval (QTc) \> 460 milliseconds for women or \> 450 milliseconds for men 5. Amylase and lipase values \> 3 × upper limit of normal 6. Patients refused standard TKI maintenance post-HSCT 7. Unable to comply with study requirements 8. Patients taking ponatinib as choice of TKI 9. Patients with documented T315I mutation
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Blastic transformation of chronic myeloid leukemia are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
The University of Hong Kong
Hong Kong, Hong Kong
More trials for these conditions
Other studies related to the condition(s) this trial covers.